Revance Therapeutics has established four new positions at the company as it prepares for the launch and commercialization of its daxibotulinumtoxinA injectable (RT002) for the treatment of glabellar lines.
Dustin Sjuts has been appointed vice president of strategy and sales, aesthetic and therapeutic; Ben Putman is vice president of digital; and Marc Korenberg is senior director of commercial operations. In addition, Erica Bazerkanian has been promoted to vice president of marketing, aesthetics and therapeutics. All four will report to Todd Zavodnick, chief commercial officer and president of aesthetics & therapeutics.
Sjuts, who previously worked with Nestle Skin Health, Alphaeon and Allergan, will head all product sales activities, championing strategies to enhance physician relations and drive new product adoption.
Putman, who previously served as senior vice president, general manager and senior vice president of creative technology and innovation at JUICE Pharma Advertising, will lead digital marketing and strategy activities.
Allergan and Zeltiq Aesthetics alumni Korenberg will manage commercial operations activities at Revance, including customer excellence and relationship management...